Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Gunilla Osswald
|
| gptkbp:collaboratesWith |
gptkb:AbbVie
gptkb:Eisai |
| gptkbp:country |
gptkb:Sweden
|
| gptkbp:developedDrug |
gptkb:lecanemab
|
| gptkbp:focusesOn |
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease neurodegenerative diseases |
| gptkbp:foundedBy |
Lars Lannfelt
|
| gptkbp:foundedYear |
2003
|
| gptkbp:headquartersLocation |
gptkb:Stockholm
|
| https://www.w3.org/2000/01/rdf-schema#label |
BioArctic
|
| gptkbp:listedOn |
gptkb:OMX_Stockholm
|
| gptkbp:notableProduct |
BAN2401 (lecanemab)
|
| gptkbp:numberOfEmployees |
~80
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
immunotherapy
antibody therapeutics |
| gptkbp:stockExchange |
gptkb:Nasdaq_Stockholm
|
| gptkbp:stockSymbol |
BIOA-B
|
| gptkbp:website |
https://www.bioarctic.com/
|
| gptkbp:bfsParent |
gptkb:HealthCap
|
| gptkbp:bfsLayer |
8
|